By the end of the study , the annualised relapse rate was higher in patients assigned to placebo ( 0.50 [ 95 % CI 0.43-0 .58 ] ) than in those assigned to teriflunomide 14 mg ( 0.32 [ 0.27-0 .38 ] ; p = 0.0001 ) or teriflunomide 7 mg ( 0.39 [ 0.33-0 .46 ] ; p = 0.0183 ) .